A prospective, observational, multicenter Real-World Evidence study to assess the effectiveness & safety of CIDMUS (sacubitril - valsartan) in Heart Failure with reduced Ejection Fraction (HFrEF) and Heart Failure with mid-range ejection fraction (HFmrEF) patients in India.

This is a prospective, observational, multicenter real-world evidence, single-arm study. The study aims to assess the effectiveness and safety of CIDMUS in both HFrEF (EF less than or equal to 40%) and HFmrEF (EF: 41% - 49%) patients, with a total enrollment of 200 subjects at baseline. The study will be carried out in India, across 10 sites in 4-6 cities with subjects who have been prescribed CIDMUS for the first time or within one week. The study comprises subjects who are at least 18 years “ old or above with a 12-month follow-up period. Potential subjects will be screened for eligibility. After meeting the eligibility criteria, the subjects will be enrolled in the study and will be assigned a Unique Identification Number (UIN) to maintain confidentiality. Subjects will be evaluated at Month 1, Month 3, Month 6, and Month 12. Safety will be assessed throughout the study period for 12 months.